These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32266710)

  • 1. The implication of 'unknown significance' variants in next-generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene.
    López-Andrade B; Bento L; Diez Campelo M; López Cadenas F; González Martín T; Lo Riso L; Novo A; Martinez-Serra J; Ballester C; Sampol A; Duran MA
    Br J Haematol; 2020 May; 189(4):e182-e184. PubMed ID: 32266710
    [No Abstract]   [Full Text] [Related]  

  • 2. Clonal dynamics of donor-derived myelodysplastic syndrome after unrelated hematopoietic cell transplantation for high-risk pediatric B-lymphoblastic leukemia.
    Schwartz JR; Walsh MP; Ma J; Lamprecht T; Wang S; Wu G; Raimondi S; Triplett BM; Klco JM
    Cold Spring Harb Mol Case Stud; 2018 Oct; 4(5):. PubMed ID: 29891567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.
    Mukherjee S
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):1-2. PubMed ID: 27865911
    [No Abstract]   [Full Text] [Related]  

  • 4. Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study.
    Aoki K; Ishikawa T; Ishiyama K; Aoki J; Itonaga H; Fukuda T; Kakihana K; Uchida N; Ueda Y; Eto T; Mori T; Kondo T; Iwato K; Morishima Y; Tanaka J; Atsuta Y; Miyazaki Y;
    Br J Haematol; 2015 Feb; 168(3):463-6. PubMed ID: 25228239
    [No Abstract]   [Full Text] [Related]  

  • 5. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
    Hamilton BK; Rybicki L; Hirsch C; Przychodzen B; Nazha A; Gerds AT; Hanna R; Kalaycio M; Sekeres MA; Sobecks R; de Lima M; Majhail NS; Maciejewski J
    Bone Marrow Transplant; 2019 Aug; 54(8):1281-1286. PubMed ID: 30655603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.
    Della Porta MG; Alessandrino EP
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1260-1. PubMed ID: 25020100
    [No Abstract]   [Full Text] [Related]  

  • 8. The Art of Transplantation: Conditioning Intensity for Allogeneic Hematopoietic Stem Cell Transplantation.
    Ragon BK
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):e71-e72. PubMed ID: 30562588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.
    Gurnari C; Robin M; Godley LA; Drozd-Sokołowska J; Włodarski MW; Raj K; Onida F; Worel N; Ciceri F; Carbacioglu S; Kenyon M; Aljurf M; Bonfim C; Makishima H; Niemeyer C; Fenaux P; Zebisch A; Hamad N; Chalandon Y; Hellström-Lindberg E; Voso MT; Mecucci C; Duarte FB; Sebert M; Sicre de Fontbrune F; Soulier J; Shimamura A; Lindsley RC; Maciejewski JP; Calado RT; Yakoub-Agha I; McLornan DP
    Lancet Haematol; 2023 Dec; 10(12):e994-e1005. PubMed ID: 37898151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD34+ cell dose in allogeneic transplantation: weight considerations.
    Basquiera AL; Abichaín P; Damonte JC; García JJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):196. PubMed ID: 25270957
    [No Abstract]   [Full Text] [Related]  

  • 11. Transplants in myelodysplastic syndromes.
    Wetzko K; Platzbecker U
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1011-22. PubMed ID: 25459176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mixed donor chimaerism in recipient fingernails following reduced-intensity conditioning haematopoietic SCT.
    Pearce L; Lim ZY; Usai M; Ho AY; Mufti GJ; Pagliuca A
    Bone Marrow Transplant; 2008 Sep; 42(5):361-2. PubMed ID: 18622424
    [No Abstract]   [Full Text] [Related]  

  • 13. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
    Oran B
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
    Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
    Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity and nonmyeloablative conditioning regimens.
    Foss F; van Besien K
    Cancer Treat Res; 2009; 144():209-32. PubMed ID: 19779868
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
    Guièze R; Damaj G; Pereira B; Robin M; Chevallier P; Michallet M; Vigouroux S; Beguin Y; Blaise D; El Cheikh J; Roos-Weil D; Thiebaut A; Rohrlich PS; Huynh A; Cornillon J; Contentin N; Suarez F; Lioure B; Mohty M; Maillard N; Clement L; François S; Guillerm G; Yakoub-Agha I
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):240-247. PubMed ID: 26256942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with myelodysplastic syndromes.
    Christopeit M; Badbaran A; Alawi M; Zabelina T; Zeck G; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2016 Sep; 97(3):288-96. PubMed ID: 26680262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation.
    Ringdén O
    Stem Cells Dev; 2009 Nov; 18(9):1243-6. PubMed ID: 19905962
    [No Abstract]   [Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation for myelodysplastic syndrome.
    Parmar S; de Lima M
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S37-44. PubMed ID: 19857589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.